Cerebrolysin and Neurodevelopment in Preterm Infants

Cerebral Palsy Clinical Trial

Official title:

Efficacy and Safety of Cerebrolysin on Neurodevelopmental Outcome of Preterm Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03506841
• Other study ID #: Mansoura NICU 2016
• Status: Completed
• Phase: Phase 1
• Start date: June 2016
• Est. completion date: June 2019

Study information

• Verified date: March 2021
• Source: Mansoura University Children Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall aim of the study is to assess the effect of Cerebrolysin on physical and mental development of preterm infants by Denver Scale II at different ages of 5, 7 and 12 months

Description:

There is an inverse relationship between birth weight or gestational age and risk for developmental impairment, with increasing incidence as birth weight or gestational age decreases. Serious impairment, defined as problems in body function or structure which may be temporary or permanent, is generally a more stable condition and typically leads to a disability requiring rehabilitation. Mild impairment is a more reversible condition amenable to early intervention. Studies that have followed extremely preterm and extremely low birth weight infants into school age and early adulthood have shown higher rates of motor, cognitive or behavioral impairments as compared with infants born at term. The neurologic consequences of extreme prematurity range from mild behavioral and cognitive defects to severe disability. Perinatal neuroprotection aims to reduce these outcomes. Cerebrolysin is a porcine brain-derived peptide preparation that acts like endogenous neurotrophic factors. It is produced by a standardized enzymatic breakdown of lipid-free brain protein powder and consists of low molecular weight peptides and free amino acids. The pharmacodynamic effects of Cerebrolysin can be categorized in terms of neuronal survival (e.g. trophic and survival promoting actions), neuroprotection (e.g. limiting neuronal dysfunction, especially in adverse conditions), neuroplasticity (e.g. adaptive responses to changing conditions) and neurogenesis (e.g. promoting differentiation of progenitor cells). We aim to assess the effect of Cerebrolysin on physical and mental development of preterm infants at different ages of life at 5, 7 and 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Months to 1 Year

Eligibility

Inclusion Criteria:

• High risk preterm infants born with gestational age less than 32 weeks and have a corrected postnatal age of 5 months at time of enrollment. Included preterm infants should have one or more of the following risk factors which may affect their neurodevelopmental outcome.

1. Infants diagnosed with bronchopulmonary dysplasia requiring oxygen therapy more than 30% FIO2 at 36 weeks corrected gestational age.

2. Infants with culture proven early or late onset neonatal sepsis with or without neonatal meningitis.

3. Infants diagnosed to have peri- ventricular leukomalacia diagnosed by brain imaging.

Exclusion Criteria:

1. Patient with persistent uncontrolled fits (all possible reasons for these uncontrolled seizures, including non-epileptic seizures, pseudo intractability, and medically refractory epilepsy.

2. Patient with brain malformation.

Related Conditions & MeSH terms

• Cerebral Palsy
• Infant Development
• Premature Birth
• Preterm Infant

Intervention

Drug:
• Cerebrolysin
Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).

Locations

Country	Name	City	State
Egypt	Mansoura University Children Hospital	Mansourah	El Dakahlya

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University Children Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neurodevelopmental outcome	Assessment of the physical and mental functions of preterm infant by Denver Developmental Screening Test II (DDST II)	9 months
Secondary	Side effects of cerebrolysin therapy	Sweating, dizziness, increased heart rate and arrhythmia, loss of appetite, diarrhea, constipation, nausea, irritability, insomnia, and allergic reactions.	9 months